摘要
背景:肾病是糖尿病的一种使人虚弱的并发症,与肾功能衰竭风险增加有关,导致患者的生活质量较差,最终导致死亡。早期干预对于增进肾病患者的健康至关重要。不幸的是,它不是肾损伤的早期标志物,白蛋白尿是糖尿病和高血压患者肾功能衰退的一个众所周知的预测指标。 目的:评估新的和精确的标记物对于预测肾病的早期发作和进展是必要的。即使在出现临床症状(无微量白蛋白尿)之前,找到可预测肾脏损伤的早期标记也很重要。 结果:使用替代标志物如血清肌酸酐预防和治疗肾脏疾病未被证明是已被证明可降低发病率或死亡率的干预措施的更好指标。许多研究已经阐明了肾损伤标记物的重要性。本文介绍了尿标记物如nephrin,Cystatin C,Monocyte chemoattractant protein(MCP-1),中性粒细胞明胶酶相关脂质运载蛋白(NGAL),肾损伤分子-1(KIM-1)和巢蛋白的意义,早期肾功能不全。 结论:虽然药物治疗取得了显着进展,但与肾病有关的发病率和死亡率依然高居不下。除了血清标记物之外,尿标记物可以更好地预测糖尿病患者对肾脏的损伤进展。
关键词: 糖尿病,炎症,肾脏疾病,尿路标记,肾病,肾功能衰竭。
图形摘要
Current Drug Targets
Title:Early Urinary Markers for Diabetic and Other Kidney Diseases
Volume: 19 Issue: 7
关键词: 糖尿病,炎症,肾脏疾病,尿路标记,肾病,肾功能衰竭。
摘要: Background: Nephropathy is a debilitating complication of diabetes associated with increased risk for renal failure, leading to poor quality of life of the affected patients and eventually to mortality. Early intervention is crucial to enhance the well-being of the patients with nephropathy. Albuminuria is a well-known predictor of weak renal outcomes in patients with diabetes and hypertension, unfortunately, it is not an early marker for kidney injury.
Objective: Assessment of new and precise markers is necessary to predict the early onset and progression of nephropathy. It is important to find early markers which could predict kidney injury even before the clinical signs (no microalbuminuria) appear.
Results: Prevention and therapy for kidney diseases using surrogate markers such as serum creatinine have not proven to be better indicators for interventions that have been shown to decrease morbidity or mortality. A number of studies have elucidated the importance of kidney injury markers. This article describes the significance of urinary markers such as nephrin, Cystatin C, Monocyte chemoattractant protein (MCP-1), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM- 1) and nestin, which are associated with early renal dysfunction.
Conclusion: Although significant advances have been made in medical therapy, the degree of morbidity and mortality associated with kidney diseases remain despondently high. Besides the serum markers, urinary markers may provide a better prediction of progression of the damage to the kidneys in diabetic patients.
Export Options
About this article
Cite this article as:
Early Urinary Markers for Diabetic and Other Kidney Diseases, Current Drug Targets 2018; 19 (7) . https://dx.doi.org/10.2174/1389450119666180319124639
DOI https://dx.doi.org/10.2174/1389450119666180319124639 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology MicroRNAs and the Warburg Effect: New Players in an Old Arena
Current Gene Therapy Pathophysiology of Arterial Hypertension: Insights from Pediatric Studies
Current Pediatric Reviews On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry The Relationship Between HIV Infection and Cardiovascular Disease
Current Cardiology Reviews The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine III. Angiogenesis: Complexity of Tumor Vasculature and Microenvironment
Current Pharmaceutical Design Hot Melt Extruded and Injection Moulded Dosage Forms: Recent Research and Patents
Recent Patents on Drug Delivery & Formulation Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy PPARγ Activation Improves the Molecular and Functional Components of Ito Remodeling by Angiotensin II
Current Pharmaceutical Design "Heart Failure: Meeting the Challenges of Surveillance and Knowledge Translation in Resource-poor Settings"
Current Cardiology Reviews Olmesartan Reduces Pentosidine Production and Ameliorates Fragility of Bone in Ovariectomized Fructose-Fed Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Study of Prolactin Permeation Through the Pericardium and Its Bioavailability
Protein & Peptide Letters Hemolysis-Associated Pulmonary Hypertension in Sickle Cell Disease: Global Disruption of the Arginine-Nitric Oxide Pathway
Current Hypertension Reviews Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Pharmacological Effects of RAAS Blockade in Ischemic Nephropathy
Current Drug Metabolism Acute Myocardial Infarction: High Risk Ventricular Tachyarrhythmias and Admission Glucose Level in Patients with and without Diabetes Mellitus
Current Diabetes Reviews Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial [Hot Topic: Recent Advances and Future Prospect in Protease Targeting (Executive Editor: B. Turk)]
Current Pharmaceutical Design